As the landscape of obesity treatment evolves, the intersection of pharmacologic therapies and surgical options becomes increasingly nuanced. In this episode, Dr. Janey Pratt and I explore when and how glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) can be used in relation to bariatric surgery. We discuss surgical candidacy criteria, benefits of bariatric surgery, long-term outcomes, and how to match treatment strategies to patient-specific characteristics, preference

Dr. Charles Vega and I collaborated on a 10-part educational video series focused on obesity management in the GLP-1 receptor agonist era. The series explores common clinical challenges encountered in primary care, with discussions led by leading experts in obesity medicine. I host several episodes and will be sharing them over the coming weeks. Episode 2 summary: Patients with obesity experience significant stigmas that often play a role in their decisions on how to manage t

It’s understandable, given the societal stigma of obesity, to feel offended if your doctor raises the issue of weight. But your doctor...